TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 388085

Group type: EXPERIMENTAL
Intervention: Methicillin for 3 days
Number of subjects: 105

Group type: COMPARATOR
Intervention: Saline-placebo for 3 days
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Cephalothin prophylaxis
Number of subjects: 105
Study: 31255371

Group type: EXPERIMENTAL
Intervention: Nutritional counseling plus a low-cost, intradialytic, protein-rich meal (200 mL milk plus two egg whites) thrice weekly for 3 months.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nutritional counseling alone.
Number of subjects: 0
Study: 31074184

Group type: EXPERIMENTAL
Intervention: Acetazolamide 250–500 mg daily plus bumetanide 1–2 mg bid
Number of subjects: 34

Group type: COMPARATOR
Intervention: High-dose loop diuretics (bumetanide bid with daily dose twice the oral maintenance dose)
Number of subjects: 34
Study: 28304210

Group type: EXPERIMENTAL
Intervention: CAF + CMX
Number of subjects: 18

Group type: COMPARATOR
Intervention: CAF
Number of subjects: 18
Study: 26115762

Group type: EXPERIMENTAL
Intervention: Home-based exercise group for AS
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Hospital-based exercise group for AS
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Home-based exercise group for MS
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Hospital-based exercise group for MS
Number of subjects: 80
Study: 23286595

Group type: EXPERIMENTAL
Intervention: Proactive telephone counseling with tailored self‐directed materials (including nicotine patches, if not contraindicated)
Number of subjects: 496

Group type: COMPARATOR
Intervention: Tailored self‐directed materials (including nicotine patches, if not contraindicated)
Number of subjects: 496
Study: 21585706

Group type: EXPERIMENTAL
Intervention: Bevacizumab + cisplatin-based chemotherapy
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Pemetrexed + cisplatin
Number of subjects: 1000
Study: 19050829

Group type: EXPERIMENTAL
Intervention: 30 mg zinc daily for 4 weeks
Number of subjects: 16
Study: 16962106

Group type: EXPERIMENTAL
Intervention: Cumulus-aided embryo transfer with cocultured embryos and expanded cumulus cells
Number of subjects: 517

Group type: COMPARATOR
Intervention: Control group (coculture without cumulus-aided embryo transfer)
Number of subjects: 517
Study: 15623197

Group type: EXPERIMENTAL
Intervention: Local symptoms of SVT (pain, erythema, swelling)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Thrombus size
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: DVT diagnosis
Number of subjects: 46
Study: 12166338

Group type: EXPERIMENTAL
Intervention: Ramosetron 0.3 mg
Number of subjects: 194

Group type: COMPARATOR
Intervention: Granisetron 3.0 mg
Number of subjects: 194
Study: 9892475

Group type: EXPERIMENTAL
Intervention: 25 microg/kg s.c. rHuIL-10
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 25 microg/kg i.v. rHuIL-10
Number of subjects: 17
Study: 8589298

Group type: EXPERIMENTAL
Intervention: CT 110 membrane
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: CT 190 membrane
Number of subjects: 6
Study: 1976664

Group type: EXPERIMENTAL
Intervention: Cetirizine, 20 mg/day for 4 days
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 416195

Group type: EXPERIMENTAL
Intervention: Peripheral total parenteral nutrition (TPN) consisting of casein hydrosylate, dextrose, and soybean emulsion
Number of subjects: 40

Group type: COMPARATOR
Intervention: Nutrition with dextrose and electrolytes (Control)
Number of subjects: 40
Study: 31558398

Group type: EXPERIMENTAL
Intervention: Intravenous thiamine (600 mg on the day of surgery, and 400 mg/day on postoperative days 1, 2, and 3)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 30412606

Group type: EXPERIMENTAL
Intervention: PEIC (2 x 5)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: PEIC (5 x 2)
Number of subjects: 28

Group type: COMPARATOR
Intervention: SHAM (2 x 5)
Number of subjects: 28

Group type: COMPARATOR
Intervention: SHAM (5 x 2)
Number of subjects: 28
Study: 25648738

Group type: EXPERIMENTAL
Intervention: 250 μg/day B12 supplementation
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 24365043

Group type: COMPARATOR
Intervention: parnaparin 8500 UI aXa od for ten days followed by placebo for 20 days
Number of subjects: 664

Group type: EXPERIMENTAL
Intervention: parnaparin 8500 UI aXa od for ten days followed by 6400 UI aXa od for 20 days
Number of subjects: 664

Group type: EXPERIMENTAL
Intervention: parnaparin 4250 UI aXa od for 30 days
Number of subjects: 664
Study: 22584353

Group type: EXPERIMENTAL
Intervention: Oral ganciclovir (1 g t.i.d.)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Valacyclovir (2 g q.i.d.)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Preemptive therapy with valganciclovir (900 mg b.i.d. for a minimum of 14 days)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Deferred therapy
Number of subjects: 141
Study: 19800056

Group type: EXPERIMENTAL
Intervention: Rational feeding actions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-rational feeding actions
Number of subjects: 0
Study: 18030070

Group type: EXPERIMENTAL
Intervention: Trimetazidine (20 mg tid)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Usual drug therapy
Number of subjects: 61
Study: 16202045

Group type: EXPERIMENTAL
Intervention: Removable partial dentures including molar replacement (RPD_group)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Retain a premolar occlusion (PROC_group)
Number of subjects: 34
Study: 12133061

Group type: EXPERIMENTAL
Intervention: Radical prostatectomy
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Radical radiotherapy
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Brachytherapy
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Watchful waiting
Number of subjects: 196
Study: 10484858

Group type: EXPERIMENTAL
Intervention: Subcutaneous morphine
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Subcutaneous fentanyl
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 23
Study: 7473034

Group type: EXPERIMENTAL
Intervention: Change in job role quality
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Change in marital role quality
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Change in marital experience (for women)
Number of subjects: 210
Study: 1710631

Group type: EXPERIMENTAL
Intervention: Histamine hydrochloride (10 and 100 mg/ml)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Codeine phosphate (9%)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Substance P (50 and 500 ng per injection site)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Phentolamine (20 micrograms per injection site)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Carbachol (1 microgram per injection site)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Histamine, codeine phosphate, and substance P
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Microscopic examination of skin mast cells
Number of subjects: 82
Study: 6754512

Group type: EXPERIMENTAL
Intervention: Org OD 14
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study: 31609865

Group type: EXPERIMENTAL
Intervention: Single 12.5 mg naltrexone oral dose (SI group)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Escalating dosage regimen starting from 50 μg up to a cumulative dose of 12.5 mg (ED group)
Number of subjects: 124
Study: 31046713

Group type: EXPERIMENTAL
Intervention: Health and wellbeing financial incentives offered to SMEs
Number of subjects: 0

Group type: COMPARATOR
Intervention: No monetary incentives (control group)
Number of subjects: 0
Study: 28444488

Group type: EXPERIMENTAL
Intervention: Prophylactic swallowing exercises, completed twice daily
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study: 26837474

Group type: EXPERIMENTAL
Intervention: Selumetinib (75 mg twice daily) plus Docetaxel (75 mg/m2, intravenously on day 1 of every 21-day cycle)
Number of subjects: 634

Group type: COMPARATOR
Intervention: Placebo plus Docetaxel (75 mg/m2, intravenously on day 1 of every 21-day cycle)
Number of subjects: 634
Study: 24638003

Group type: EXPERIMENTAL
Intervention: Imatinib (1 year of adjuvant therapy)
Number of subjects: 645

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 645

Group type: EXPERIMENTAL
Intervention: Adjuvant imatinib
Number of subjects: 645
Study: 22431864

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 40 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg plus fenofibrate 200 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg plus omega-3 fatty acids 2 g
Number of subjects: 60
Study: 20707696

Group type: EXPERIMENTAL
Intervention: Combination peer-educator and manager-training intervention
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: All three interventions
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control community (usual care)
Number of subjects: 110
Study: 17952029

Group type: EXPERIMENTAL
Intervention: Rigid Bonfils endoscope (RBI group, n=59)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Flexible fiberscope (FFI group, n=57)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Flexible fiberscope (FFI group)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Rigid Bonfils endoscope (RBI group)
Number of subjects: 116
Study: 16277693

Group type: EXPERIMENTAL
Intervention: Pyridoxine supplementation (50 mg daily for 30 days)
Number of subjects: 0
Study: 12126938

Group type: EXPERIMENTAL
Intervention: Pirfenidone (800 mg, t.i.d.)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Pirfenidone
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 10583306

Group type: EXPERIMENTAL
Intervention: GHRP-6 after dexamethasone
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: GHRH after dexamethasone
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: GHRP-6 plus GHRH after dexamethasone
Number of subjects: 16

Group type: COMPARATOR
Intervention: GHRP-6 after placebo
Number of subjects: 16

Group type: COMPARATOR
Intervention: GHRH after placebo
Number of subjects: 16

Group type: COMPARATOR
Intervention: GHRP-6 plus GHRH after placebo
Number of subjects: 16
Study: 7784126

Group type: EXPERIMENTAL
Intervention: SPf66 vaccine adjuvanted with alum
Number of subjects: 0

Group type: COMPARATOR
Intervention: Colombian produced SPf66
Number of subjects: 0
Study: 1316066

Group type: EXPERIMENTAL
Intervention: Lomefloxacin 400 mg oral dose
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Lomefloxacin up to 800 mg and multiple doses up to 600 mg twice daily (1,200 mg/day)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Lomefloxacin (all dosage regimens)
Number of subjects: 6
Study: 2867573

Group type: EXPERIMENTAL
Intervention: Buspirone t.i.d.
Number of subjects: 12

Group type: COMPARATOR
Intervention: Flurazepam
Number of subjects: 12

Group type: COMPARATOR
Intervention: Triazolam
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Buspirone
Number of subjects: 12
Study: 30927036

Group type: EXPERIMENTAL
Intervention: XELOX and trastuzumab
Number of subjects: 45
Study: 29396020

Group type: EXPERIMENTAL
Intervention: Low-intensity shockwave therapy sessions once per week for 6 weeks (group A)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Low-intensity shockwave therapy sessions twice per week for 6 weeks (group B)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Repeat treatment after 6 months (group A received 2 sessions per week, group B received 1 session per week)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Total number of sessions (6, 12, and 18 sessions)
Number of subjects: 42
Study: 26465919

Group type: EXPERIMENTAL
Intervention: Minocycline (100 mg twice daily)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 25791068

Group type: EXPERIMENTAL
Intervention: Lung age concept used in smoking cessation counseling
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Lung age concept
Number of subjects: 29
Study: 23980091

Group type: EXPERIMENTAL
Intervention: Gefitinib 250 mg per day for 2 years
Number of subjects: 503

Group type: COMPARATOR
Intervention: Placebo for 2 years
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: Gefitinib for patients with EGFR wild-type tumors
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: Gefitinib for patients with EGFR mutation-positive tumors
Number of subjects: 503
Study: 21534899

Group type: EXPERIMENTAL
Intervention: Process redesign to streamline clinical pathways for elective surgery in a dedicated elective surgery facility.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dedicated elective surgery facility
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical process redesign
Number of subjects: 0
Study: 18339031

Group type: EXPERIMENTAL
Intervention: Salbutamol (PC(20) = 10.79 mg/L, PC(35) = 8.55 mg/L)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Normal controls (PC(20) = 237.68 mg/L, PC(35) = 88.72 mg/L)
Number of subjects: 22
Study: 16568461

Group type: EXPERIMENTAL
Intervention: Brief Cognitive Behavioral Intervention (B‐CBT)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Assessment Condition (AC)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Supportive Counseling (SC)
Number of subjects: 90
Study: 12674152

Group type: EXPERIMENTAL
Intervention: Antibiotic misuse in the community
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Factors affecting patient compliance to therapy
Number of subjects: 0
Study: 10886473

Group type: EXPERIMENTAL
Intervention: Pap test performed as part of pelvic examination in the intervention group
Number of subjects: 111

Group type: COMPARATOR
Intervention: Usual care group encouraged to schedule a Pap test later
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Follow-up for abnormal Pap smears in the intervention group
Number of subjects: 111

Group type: COMPARATOR
Intervention: Follow-up for abnormal Pap smears in the gynecology clinic
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Abnormality rate of Pap smears in urgent care clinic
Number of subjects: 111

Group type: COMPARATOR
Intervention: Abnormality rate of Pap smears in gynecology clinic
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Specimen adequacy of Pap smears in urgent care clinic
Number of subjects: 111

Group type: COMPARATOR
Intervention: Specimen adequacy of Pap smears in gynecology clinic
Number of subjects: 111
Study: 9386685

Group type: EXPERIMENTAL
Intervention: Preoperative intraaortic balloon pump (IABP) treatment
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (no preoperative IABP)
Number of subjects: 48
Study: 7957346

Group type: EXPERIMENTAL
Intervention: Dexamethasone intervention (10 mg in 24 h)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Intravenous administration of 20 mCi (740 MBq) of technetium‐99m methylene diphosphonate (99mTc‐MDP)
Number of subjects: 77
Study: 3591298

Group type: COMPARATOR
Intervention: F1 (1.9 g of protein and 72 kcal per 100 ml)
Number of subjects: 30

Group type: COMPARATOR
Intervention: F2 (2.7 g of protein and 69 kcal per 100 ml)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: HM (0.96 g of protein and 65 kcal per 100 ml)
Number of subjects: 30
Study: 31219152

Group type: EXPERIMENTAL
Intervention: STARTS intervention (Strategies to Avoid Returning to Smoking)
Number of subjects: 300

Group type: COMPARATOR
Intervention: SUPPORT intervention (attention-controlled comparison)
Number of subjects: 300
Study: 29687303

Group type: EXPERIMENTAL
Intervention: Guava leaf extract (1 g daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Guava leaf extract
Number of subjects: 0
Study: 27839596

Group type: EXPERIMENTAL
Intervention: Blurred lens with target laser on
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Blurred lens with target laser turned off
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: +3.0 D lens with target laser on
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: +3.0 D lens with target laser turned off
Number of subjects: 11
Study: 27536454

Group type: EXPERIMENTAL
Intervention: Pranlukast
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 22580856

Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CyA)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Tacrolimus (Tac)
Number of subjects: 53
Study: 20048227

Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy (IPT)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy guided self-help (CBTgsh)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Behavioral weight loss treatment (BWL)
Number of subjects: 205
Study: 17875007

Group type: EXPERIMENTAL
Intervention: peginterferon alpha‐2a plus ribavirin
Number of subjects: 380

Group type: COMPARATOR
Intervention: peginterferon alpha‐2b plus ribavirin
Number of subjects: 380
Study: 16156881

Group type: EXPERIMENTAL
Intervention: Ritonavir 100 mg twice-daily added to nelfinavir 1250 mg twice-daily regimen
Number of subjects: 16

Group type: COMPARATOR
Intervention: Nelfinavir 1250 mg twice-daily regimen without ritonavir
Number of subjects: 16
Study: 12360161

Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy
Number of subjects: 2588
Study: 8017414

Group type: EXPERIMENTAL
Intervention: Intravenous nitroglycerin through PVC administration set
Number of subjects: 140

Group type: COMPARATOR
Intervention: Intravenous nitroglycerin through polyethylene administration set
Number of subjects: 140
Study: 3174725

Group type: EXPERIMENTAL
Intervention: Liquid 'Diasorb' (smectite)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Loperamide
Number of subjects: 80
Study: 31169407

Group type: COMPARATOR
Intervention: Sevoflurane anaesthesia
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Total intravenous anaesthesia (TIVA) with Propofol
Number of subjects: 20
Study: 28771503

Group type: EXPERIMENTAL
Intervention: Narrowband UVB treatment
Number of subjects: 1749
Study: 26084281

Group type: EXPERIMENTAL
Intervention: Progressive resistance exercise program, performed twice a week for 15 weeks
Number of subjects: 130

Group type: COMPARATOR
Intervention: Active control group
Number of subjects: 130
Study: 23550694

Group type: EXPERIMENTAL
Intervention: Self-hypnosis group (three 1-h lessons in self-hypnosis with audio-recordings)
Number of subjects: 1222

Group type: EXPERIMENTAL
Intervention: Relaxation group (three 1-h lessons in relaxation methods and mindfulness with audio-recordings)
Number of subjects: 1222

Group type: COMPARATOR
Intervention: Usual-care group (only usual antenatal care)
Number of subjects: 1222

Group type: EXPERIMENTAL
Intervention: Self-hypnosis group
Number of subjects: 1222

Group type: EXPERIMENTAL
Intervention: Relaxation group
Number of subjects: 1222

Group type: COMPARATOR
Intervention: Usual-care group
Number of subjects: 1222
Study: 21804375

Group type: EXPERIMENTAL
Intervention: Esomeprazole/amoxicillin/levofloxacin (EAL) - 40 mg esomeprazole twice daily, 1 g amoxicillin twice daily and 500 mg levofloxacin once daily for 7 days
Number of subjects: 90

Group type: COMPARATOR
Intervention: Esomeprazole/amoxicillin/metronidazole (EAM) - 40 mg esomeprazole twice daily, 1 g amoxicillin twice daily and 250 mg metronidazole 4 times daily for 14 days
Number of subjects: 90
Study: 19142961

Group type: EXPERIMENTAL
Intervention: Alternative mouse
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Forearm support board
Number of subjects: 206

Group type: COMPARATOR
Intervention: Control group (no intervention mentioned)
Number of subjects: 206
Study: 17042884

Group type: EXPERIMENTAL
Intervention: Quetiapine monotherapy (up to 800 mg/day)
Number of subjects: 1006

Group type: EXPERIMENTAL
Intervention: Quetiapine + Lithium/Divalproex (up to 800 mg/day)
Number of subjects: 1006

Group type: COMPARATOR
Intervention: Haloperidol monotherapy
Number of subjects: 1006

Group type: COMPARATOR
Intervention: Lithium monotherapy
Number of subjects: 1006

Group type: EXPERIMENTAL
Intervention: Quetiapine monotherapy
Number of subjects: 1006

Group type: EXPERIMENTAL
Intervention: Quetiapine + Lithium/Divalproex
Number of subjects: 1006

Group type: COMPARATOR
Intervention: Lithium
Number of subjects: 1006

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 1006
Study: 14742097

Group type: EXPERIMENTAL
Intervention: Ephedrine (50 mg)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 11315997

Group type: EXPERIMENTAL
Intervention: Fractal analysis of trabecular bone texture (H parameter)
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Low H values combined with BMD measurements
Number of subjects: 304
Study: 9596457

Group type: EXPERIMENTAL
Intervention: Sumatriptan nasal spray 20 mg
Number of subjects: 1086

Group type: EXPERIMENTAL
Intervention: Sumatriptan nasal spray 10 mg
Number of subjects: 1086

Group type: EXPERIMENTAL
Intervention: Sumatriptan nasal spray 5 mg
Number of subjects: 1086

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1086

Group type: EXPERIMENTAL
Intervention: Sumatriptan nasal spray
Number of subjects: 1086
Study: 7696164

Group type: EXPERIMENTAL
Intervention: AVP induction chemotherapy (adriamycin, etoposide, cisplatin given every four weeks for four cycles)
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: EVA induction chemotherapy (cyclophosphamide, etoposide, adriamycin given every four weeks for four cycles)
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: MOC/AVP induction chemotherapy (methotrexate, vincristine, cyclophosphamide alternating with adriamycin, etoposide, cisplatin for two cycles)
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Combined-modality maintenance therapy (radiation therapy to the chest followed by MOC/EVA chemotherapy)
Number of subjects: 266

Group type: COMPARATOR
Intervention: Maintenance chemotherapy alone (without consolidating chest irradiation)
Number of subjects: 266
Study: 2622586

Group type: EXPERIMENTAL
Intervention: Ritodrine and potassium chloride
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Carnitine (2 g infusion with phleboclysis)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Tocolytics per os (oral)
Number of subjects: 42
Study: 981

Group type: EXPERIMENTAL
Intervention: 11.2% mafenide acetate cream
Number of subjects: 37

Group type: COMPARATOR
Intervention: 5% mafenide acetate cream
Number of subjects: 37

Group type: COMPARATOR
Intervention: Carrier cream without glycerol
Number of subjects: 37
Study: 30782522

Group type: EXPERIMENTAL
Intervention: Approach-Bias Modification (AppBM) training
Number of subjects: 149

Group type: COMPARATOR
Intervention: Sham training
Number of subjects: 149

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 149